Biotech Insider Alert
January 03, 2015 at 11:05 AM EST
Touting a $4 Stock with $28M in sales that has a new drug in Phase trials for Uveitis – eye disease. It has been granted ”Orphan Status” by FDA and Phase trial data is due out very soon. ?What is the stock and is this real? He wants $1950 for one year subscription to the […]
